What the studies show
In a 10-man double-blind crossover, Melanotan II produced clinically apparent erections in most treated men, far exceeding placebo — small, early, never taken to phase 3.
“Mean duration of tip rigidity greater than 80% was 38.0 minutes with Melanotan-II and 3.0 with placebo (p=0.0045).”
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: a double-blind, placebo-controlled crossover study.J Urol, 1998;160:389–39310 men, crossover; the erection data.
In context
Melanotan II is a synthetic cyclic peptide that mimics α-melanocyte-stimulating hormone. Small early trials in the 1990s showed it darkens skin and, separately, triggers erections in men — the two effects it is still sold for. It has never completed later-stage trials and is not approved anywhere. Reported harms include nausea, uncontrolled erections, darkening and change of moles, and case reports of serious events such as kidney infarction, which is why regulators warn against it.
Melanotan II is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Melanotan II proven to help with erectile function?
What studies are behind the grade?
Is Melanotan II approved for this?
Other outcomes for Melanotan II
- CSkin tanningPilot studies (n≈3–12)
- CSafety in humansadverseTrials + case reports
Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →